PubRank

Samuel Hellman

Author PubWeight™ 29.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc 2015 4.70
2 Oligometastases revisited. Nat Rev Clin Oncol 2011 2.42
3 Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2011 1.70
4 An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 2008 1.68
5 Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013 1.48
6 MicroRNA expression characterizes oligometastasis(es). PLoS One 2011 1.45
7 Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis. Int J Radiat Oncol Biol Phys 2005 1.39
8 Early prostate cancer: clinical decision-making. Lancet 2003 1.37
9 Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res 2009 1.28
10 The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer 2004 1.14
11 Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One 2012 1.11
12 Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 2004 1.09
13 Receiver operating characteristic analysis: a general tool for DNA array data filtration and performance estimation. Genomics 2003 1.08
14 Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis 2014 0.96
15 Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 2002 0.95
16 Transcriptional control of viral gene therapy by cisplatin. J Clin Invest 2002 0.85
17 Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther 2004 0.81
18 Early prostate cancer: hedonic prices model of provider-patient interactions and decisions. Int J Radiat Oncol Biol Phys 2007 0.77
19 Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis. Cancer 2003 0.77
20 Premise, promise, paradigm and prophesy. Nat Clin Pract Oncol 2005 0.76
21 Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. Cancer 2003 0.76
22 Letrozole in breast cancer. N Engl J Med 2004 0.75
23 Excision margins in high-risk malignant melanoma. N Engl J Med 2004 0.75
24 Debunking dogma and developing theses. Eur J Cancer 2005 0.75
25 Expedition Inspiration Fund for Breast Cancer Research Meeting 2003. Breast Cancer Res Treat 2003 0.75
26 An evidence-based analysis of the management of localized prostate cancer. Cancer J 2002 0.75
27 Unintended consequences. Nat Clin Pract Oncol 2007 0.75
28 Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Res Treat 2003 0.75